Diane Kalina is an experienced biotech/pharma executive with proven skills in the following areas:
• Strategic Alliances
• Business Plan and Strategy Development
• Managing start-up biotech companies
Diane has over 30 years experience including 17 years with GSK in positions such as Head of Marketing and Director of New Products and Licensing. She has developed an extensive international network and assisted over 30 pharmaceutical and biotech companies with over 60 Canadian and International agreements. She was Managing Director and co-founder of PDC Biotech. She also spent 3 years as President and Board of Director member of the successfully divested start-up biotech company YM BioSciences Inc. She has served on the boards of four publicly traded Canadian biotech companies and has completed the Chartered Director Program at McMaster University/DeGroote School of Business. Diane excels at running earlier stage companies – particularly those for which alliances are or will ultimately be a key success factor.
Patricia Griffin is a business development and drug development professional with more than 25 years of international experience in the pharmaceutical and biotechnology sector. She was most recently Managing Director and CEO and co-founder of PDC Biotech GmbH, an Austrian biotech company which successfully raised funding in Europe and advanced an early preclinical-stage drug candidate to clinical proof-of-concept with less than $10 million Cdn. Previous positions include Vice President, Business Development at GlycoDesign Inc., a Canadian biotechnology company, where she led commercialization efforts for the company’s cancer, cardiovascular and inflammation programs and established and managed international strategic partnerships. As Director of International Product Development at Ferring based in Paris, Patricia led multi-disciplinary teams to successfully complete the development program for two novel obstetrics products, and managed the company’s strategic alliance with a major US pharmaceutical company. As an independent consultant, she conducted detailed assessments of potential in-licensing opportunities for pharmaceutical companies and created business plans and product development plans for biotech companies. Patricia applies scientific rigour along with her industry experience to assist clients in developing and implementing streamlined drug development programs that not only meet regulatory requirements, but provide strategic partners and investors with the data they need to make appropriate investment decisions.
Wendy Hill is a clinical/regulatory expert with over 30 years experience in early nonclinical and clinical development and regulatory affairs in a variety of therapeutic areas including cancer, inflammation, infectious and cardiovascular disease. Wendy started her career as an epidemiologist in cancer research with the design of early phase clinical trials. She has successfully achieved approval for a number of CTA/IND filings and NDS/NDA filings in Canada, the US and Europe. Most recently, at PDC Biotech she played a key role in preparing the clinical/regulatory plan and managed all aspects of the Phase I trial including design and execution of the study to the analysis, writing of the report and publication. Previous positions include Director of Research at Knoll Canada where she was instrumental in the clinical development of several human monoclonal antibodies, Senior Director, Clinical Research at GlycoDesign and R&D Director, Inflammation and Neurology at Amgen Canada. As a private consultant she has assisted biotechnology companies in preparing and executing strategic clinical and regulatory development plans for products and devices and in performing due diligence on products for potential investors. Wendy’s impressive track record in designing and implementing successful clinical studies reflects her creativity, highly effective team management skills and wealth of expertise as well as her commitment to quality.
Linda Kurdydyk is a lawyer with over 20 years experience in intellectual property. She has worked as counsel for many institutions and life sciences companies. She was formerly a partner at an intellectual property law firm in Toronto where her clients included research laboratories, corporations, commercial investors, and researchers. Ms. Kurdydyk has a MSc in Medical Microbiology from the University of Manitoba and an LL.B from Osgoode Hall Law School. She is admitted to practice before the Canadian and United States Patent and Trademark Offices.